NCT04695977 2025-09-05
CMP-001 in Combination With Nivolumab Compared to Nivolumab Monotherapy in Subjects With Advanced Melanoma
Regeneron Pharmaceuticals
Phase 2/3 Terminated
Regeneron Pharmaceuticals
The Christie NHS Foundation Trust
Merck Sharp & Dohme LLC
European Organisation for Research and Treatment of Cancer - EORTC